Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Patients' and healthcare professionals' views of cancer follow-up: systematic review.

Lewis RA, Neal RD, Hendry M, France B, Williams NH, Russell D, Hughes DA, Russell I, Stuart NS, Weller D, Wilkinson C.

Br J Gen Pract. 2009 Jul;59(564):e248-59. doi: 10.3399/bjgp09X453576. Review.

2.

Follow-up of cancer in primary care versus secondary care: systematic review.

Lewis RA, Neal RD, Williams NH, France B, Hendry M, Russell D, Hughes DA, Russell I, Stuart NS, Weller D, Wilkinson C.

Br J Gen Pract. 2009 Jul;59(564):e234-47. doi: 10.3399/bjgp09X453567. Review.

3.

Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review.

Lewis R, Neal RD, Williams NH, France B, Wilkinson C, Hendry M, Russell D, Russell I, Hughes DA, Stuart NS, Weller D.

J Adv Nurs. 2009 Apr;65(4):706-23. doi: 10.1111/j.1365-2648.2008.04927.x. Review.

PMID:
19278415
4.

Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.

Stuart NS, McIllmurray MB, Bishop JL, Johnston SR, Price CG, O'Reilly SM, Joffe JK, Neave F, Whipp EC.

Clin Oncol (R Coll Radiol). 2008 Mar;20(2):152-6.

PMID:
18083354
5.

Trastuzumab for early breast cancer.

Stuart NS, Bishop J, Bale C.

Lancet. 2006 Jan 14;367(9505):107-8. No abstract available.

PMID:
16413865
6.

Barriers to following dietary recommendations in Type 2 diabetes.

Vijan S, Stuart NS, Fitzgerald JT, Ronis DL, Hayward RA, Slater S, Hofer TP.

Diabet Med. 2005 Jan;22(1):32-8.

7.

Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.

Possinger K, Kaufmann M, Coleman R, Stuart NS, Helsing M, Ohnmacht U, Arning M.

Anticancer Drugs. 1999 Feb;10(2):155-62.

PMID:
10211545
8.

Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Central Lymphoma Group.

Bailey NP, Stuart NS, Bessell EM, Child JA, Norfolk D, Fletcher J, Grieve RJ, Simmons AV, Barnard DL, Jack A, Farish J, Dunn J, Woodroffe CM, Stack C, Cullen MH.

Ann Oncol. 1998 Jun;9(6):633-8.

9.

More money is needed to care for patients with cancer.

Leonard RC, Smith IE, Coleman RE, Malpas JS, Nicolson M, Cassidy J, Jones A, McIllmurray MB, Stuart NS, Woll PJ, Whitehouse JM.

BMJ. 1997 Sep 27;315(7111):811-2. No abstract available.

10.

A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer.

Stuart NS, Warwick J, Blackledge GR, Spooner D, Keen C, Taylor AR, Tyrell C, Webster DJ, Earl H.

Eur J Cancer. 1996 Oct;32A(11):1888-92.

PMID:
8943670
11.

ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.

Cullen MH, Stuart NS, Woodroffe C, Murphy A, Fletcher J, Blackledge GR, Child JA, Grieve RJ, Jones EL.

J Clin Oncol. 1994 Apr;12(4):779-87.

PMID:
7512132
12.

A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy.

Philip PA, Thompson CH, Carmichael J, Rea D, Mitchell K, Taylor DJ, Stuart NS, Dennis I, Rajagopalan B, Ganesan T, et al.

Cancer Res. 1993 Dec 1;53(23):5649-53.

13.

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.

Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, et al.

J Natl Cancer Inst. 1993 Nov 17;85(22):1812-8.

PMID:
8230261
14.
15.

Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma.

Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J.

J Natl Cancer Inst. 1993 Apr 7;85(7):574-8.

PMID:
8384265
16.

Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.

Kirk J, Houlbrook S, Stuart NS, Stratford IJ, Harris AL, Carmichael J.

Eur J Cancer. 1993;29A(8):1152-7.

PMID:
8518026
17.

High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines.

Stuart NS, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA, Carmichael J.

Br J Cancer. 1992 Nov;66(5):833-9.

18.

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, et al.

Br J Cancer. 1992 Feb;65(2):287-91.

19.

Quality of life after treatment for testicular cancer--the patient's view.

Stuart NS, Grundy R, Woodroffe CM, Cullen MH.

Eur J Cancer. 1990 Mar;26(3):291-4.

PMID:
2141485
20.

Long-term toxicity of chemotherapy for testicular cancer--the cost of cure.

Stuart NS, Woodroffe CM, Grundy R, Cullen MH.

Br J Cancer. 1990 Mar;61(3):479-84.

21.

The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial.

O'Brien ME, Cullen MH, Woodroffe C, Kelly K, Burman C, Palmer K, Stuart NS, Blackledge GR, Sharpe J.

Br J Cancer. 1989 Nov;60(5):759-63.

22.

The role of postoperative alkylating agent therapy in early-stage epithelial ovarian cancer.

Finn CB, Redman CW, Varma R, Luesley DM, Stuart NS, Blackledge GR.

Br J Obstet Gynaecol. 1989 Aug;96(8):1007-8. No abstract available.

PMID:
2775685
23.

Correlation of morphology, immunophenotype, and flow cytometry with remission induction and survival in high grade non-Hodgkin's lymphoma.

O'Brien CJ, Holgate C, Quirke P, Stuart NS, Ellis IO, Elston CW, Jones EL, Bird CC.

J Pathol. 1989 May;158(1):31-9.

PMID:
2754538
24.

Changing character of cervical cancer in young women.

Buxton EJ, Stuart NS, Kelly KA, Blackledge GR.

BMJ. 1989 Mar 25;298(6676):829. No abstract available.

25.

A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES)--a new dihydrofolate reductase inhibitor.

Stuart NS, Crawford SM, Blackledge GR, Newlands ES, Slack J, Hoffman R, Stevens MF.

Cancer Chemother Pharmacol. 1989;23(5):308-10.

PMID:
2706736
26.
27.

A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy.

Stuart NS, Blackledge GR, Child JA, Fletcher J, Perren TJ, O'Brien CJ, Jones EL, Ellis IO, Kavanagh JA, Kelly KA, et al.

Cancer Chemother Pharmacol. 1988;22(2):141-6.

PMID:
3409445
28.

Phase II evaluation of mitozolomide in ovarian cancer.

Harding M, Northcott D, Smyth J, Stuart NS, Green JA, Newlands E.

Br J Cancer. 1988 Jan;57(1):113-4. No abstract available.

29.

A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.

Stuart NS, Cullen MH, Priestman TJ, Blackledge GR, Tyrrell CJ.

Cancer Chemother Pharmacol. 1988;21(4):351-4.

PMID:
3163529
30.

Phase II study of Zoladex depot in advanced prostatic cancer with special reference to criteria of response and survival.

Emtage LA, Perren TJ, Stuart NS, Arkell DG, Wallace DM, Hughes MA, Cottam J, Farrar D, Young CH, Blackledge GR.

Br J Urol. 1987 Nov;60(5):436-42.

PMID:
2962689
31.

Phase II study of ifosfamide in cervical cancer.

Meanwell CA, Mould JJ, Blackledge G, Lawton FG, Stuart NS, Kavanagh J, Latief TN, Spooner D, Chetiyawardana AD.

Cancer Treat Rep. 1986 Jun;70(6):727-30.

PMID:
3089596
32.

B cell production in adult rats.

Bazin H, Platteau B, MacLennan IC, Stuart NS, Khan M, Johnson GD.

Adv Exp Med Biol. 1985;186:65-71. No abstract available.

PMID:
3876720

Supplemental Content

Loading ...
Support Center